Free tool
FAERS Monitor: Alymsys
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761231 or its brand name (Alymsys, Bevacizumab-Maly). Reports on generic versions are filed under their own applications.
Reports
201
Serious
176
88% of reports
Hospitalization
59
Death reported
38
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death17
- asthenia15
- nausea11
- neutropenia11
- decreased appetite10
- weight increased9
- fatigue8
- encephalitis7
- mucosal inflammation7
- weight decreased7
- aspartate aminotransferase increased6
- blood alkaline phosphatase increased6
- gamma-glutamyltransferase increased6
- somnolence6
- thrombocytopenia6
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 34 |
| 2023 | 41 |
| 2024 | 23 |
| 2025 | 42 |
| 2026 | 61 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,958 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| encephalitisSignal | 7 | 106.0 | 51.2 | 626 |
| gamma-glutamyltransferase increasedSignal | 6 | 28.3 | 12.9 | 132 |
| mucosal inflammationSignal | 7 | 28.0 | 13.5 | 156 |
| blood alkaline phosphatase increasedSignal | 6 | 25.3 | 11.5 | 117 |
| aspartate aminotransferase increasedSignal | 6 | 11.8 | 5.4 | 49 |
| neutropeniaSignal | 11 | 8.5 | 4.8 | 66 |
| thrombocytopeniaSignal | 6 | 5.6 | 2.6 | 18 |
| decreased appetiteSignal | 10 | 4.5 | 2.5 | 24 |
| weight increasedSignal | 9 | 4.2 | 2.2 | 19 |
| astheniaSignal | 15 | 4.2 | 2.6 | 34 |
| somnolenceSignal | 6 | 3.1 | 1.4 | 7 |
| weight decreasedSignal | 7 | 2.6 | 1.3 | 6 |
| deathSignal | 17 | 2.1 | 1.3 | 9 |
| nausea | 11 | 1.5 | 0.8 | 1 |
| fatigue | 8 | 1.1 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.